Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Bibliographic Details
Main Authors:	Ahmad Alcheikh, Griffith B. Perkins, Phillippa A. Pucar, Amelia Cecchin, Cheng Sheng Chai, Matthew Tunbridge, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Stuart Turville, Sharon Allen, Pravin Hissaria, Tatjana Banovic, P. Toby Coates, David M. Ross
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-04-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00824-8

Similar Items

Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core.
by: Pantelis Poumbourios, et al.
Published: (2023-05-01)

Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)—rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
by: Matthew Tunbridge, et al.
Published: (2022-09-01)

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
by: Anupriya Aggarwal, et al.
Published: (2022-10-01)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
by: Syed B. Ali, et al.
Published: (2022-03-01)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
by: Liqiu Jia, et al.
Published: (2022-07-01)

Increased Stability of SARS-CoV-2 Omicron Variant over Ancestral Strain
by: Alex Wing Hong Chin, et al.
Published: (2022-07-01)

An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation
by: Seoryeong Park, et al.
Published: (2024-04-01)

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice
by: Mariana Baz, et al.
Published: (2022-11-01)

Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
by: Julian Singer, et al.
Published: (2022-12-01)

Response to: “methotrexate does not cause interstitial lung disease”
by: Wei-I Lee, et al.
Published: (2020-01-01)

Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells.
by: Yanshan Zhu, et al.
Published: (2022-08-01)

Murine Models of Myelofibrosis
by: Sebastien Jacquelin, et al.
Published: (2020-08-01)

Osteolytic lesions in myelofibrosis
by: Isla Johnson, et al.
Published: (2021-07-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Treatment of primary myelofibrosis
by: Şinasi Özsoylu
Published: (2009-12-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
by: Adrián Mosquera-Orgueira, et al.
Published: (2023-01-01)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
by: Freddy Dehesa-Canseco, et al.
Published: (2023-06-01)

Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination
by: Sascha Hein, et al.
Published: (2022-05-01)

Comparison of initial clinic characteristics of hospitalized patients in Suzhou City during the COVID-19 Omicron wave with ancestral variant wave
by: Binbin Gu, et al.
Published: (2022-07-01)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
by: Barnali Srivastava, et al.
Published: (2023-09-01)

The Sarawak Myelofibrosis (SaMy) experience: Demographics and outcome of myelofibrosis patients in Sarawak, Malaysia
by: Andy Sing Ong Tang, et al.
Published: (2023-09-01)

Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
by: Miyuki Tsutsui, et al.
Published: (2019-11-01)

Confucian Identification, Ancestral Beliefs, and Ancestral Rituals in Korea
by: Jibum Kim, et al.
Published: (2022-01-01)

Embedding of HIV Egress within Cortical F-Actin
by: Anupriya Aggarwal, et al.
Published: (2022-01-01)

Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012)

Guideline for the diagnosis and management of myelofibrosis
by: Reilly, J, et al.
Published: (2012)

Stem cell transplantation in myelofibrosis
by: Nicolaus Kröger
Published: (2018-06-01)

Primary myelofibrosis in rheumatic diseases
by: Vladimir Ivanovich Vasilyev, et al.
Published: (2013-04-01)

Coexistence of hypertrophic osteoarthropathy and myelofibrosis
by: Bayram Kelle, et al.

How I Manage Myelofibrosis
by: Anca Lupu
Published: (2017-08-01)

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017-02-01)

Ancestral Lineage of SARS-CoV-2 Is More Stable in Human Biological Fluids than Alpha, Beta, and Omicron Variants of Concern
by: Taeyong Kwon, et al.
Published: (2023-02-01)

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
by: Giovanni Barosi, et al.
Published: (2012-01-01)

Ancestral houses /
by: 230942 Bence-Jones, Mark
Published: (1984)

Ancestral Reconstruction.
by: Jeffrey B Joy, et al.
Published: (2016-07-01)

Memória Ancestral
by: Laíza Ferreira
Published: (2021-11-01)

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection
by: Chansavath Phetsouphanh, et al.
Published: (2024-04-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01)